COSA 2015* Sponsored by:
Content: Therapeutic agents that potentiate the tumour-destructive capabilities of the immune system are revolutionising the treatment of many cancers, including metastatic melanoma and lung cancer. Known as immuno-oncology agents, this class of drugs represent a new era in cancer clinical management and differ considerably from surgery, chemotherapy, radiotherapy and targeted therapy-based treatments.
This symposium will provide attendees with a scientific and clinical overview of the mechanism of action, efficacy and safety of these immuno-oncology agents in patients with metastatic melanoma and lung cancer, including discussion on practical clinical considerations for patients.